The immune system is potentially qualified to detect and eliminate tumor cells, but various mechanisms developed by tumor cells allow tumor escape. Strategies selected to promote antitumor responses have included genetic modifications of tumor cells to induce expression of costimulatory molecules. Moreover, alloantigens can also act as strong enhancers of the immune response. In this work, we have associated the expression of two costimulatory members of the TNF superfamily, CD40L and CD70 along with an allogenic MHC Class I (H- 
T umor cells evade host immune surveillance via several strategies, including downmodulation of MHC Class I molecule expression, secretion of suppressive cytokines and induction of tolerance by the immune system. 1 Furthermore, it has been shown that the lack of costimulatory molecules on tumor cells results in inefficient stimulation of tumor-reactive T lymphocytes. 2 Indeed, it is well established that T lymphocytes require a costimulatory signal in addition to the antigen-specific TCR-mediated signal for full activation. The costimulatory signal can be provided by members of the Ig superfamily 3 (such as CD28, CTLA-4) and some members of the TNFR superfamily, 4, 5 including CD27, CD40, 0Â40 and 4-1BB, which are expressed on the T-cell membrane. Dendritic cells express CD40 molecules and, after interaction with the corresponding ligand CD40L on T cells, they mature and migrate to lymphoid organs where they induce the activation and proliferation of cytotoxic T-lymphocytes specific for the peptides presented by MHC Class I molecules on their surface. Upon activation, T lymphocytes express CD70 molecules and upregulate the expression of CD27. Interactions between CD27 and CD70 on T lymphocytes then induce their clonal expansion, IL-2 and IFN-g secretion and cytotoxicity.
In several murine tumor models, we and others have shown that stably transfected tumor cells, expressing CD40L 6, 7 or CD70, 8, 9 were able to enhance an antitumor response and favor a long-lasting immune memory. However in the MHC Class I-negative B16F10 murine melanoma model, the antitumor responses induced with CD40L 6 or CD70 8 expressions are slight. Additionally, expression of allogenic antigens can contribute to the immunogenic properties of tumor cells. Indeed, it has been shown that expression of allogenic histocompatibility antigens acts like an immune adjuvant and can induce a strong nonspecific immune response through secretion of Th1 cytokines. 10, 11 The strong immune response induced against the alloantigen should enhance the specific immunity directed against tumorassociated antigens (TAAs) by activation of innate immunity and by secretion of cytokines.
In this study, we explored the murine MHC Class Inegative melanoma B16F10 (H-2 b ) model. This tumor is very aggressive and its rejection in vivo requires highly efficient stimulation of the immune system. Following this objective, we evaluated the efficiency of the association of CD40L and CD70 costimulatory molecules expression with the expression of an allogenic MHC Class I molecule (H-2K d ) to induce stronger antimelanoma immunity. CD40L and CD70 expression on B16F10 tumor cells should enhance the specific immune response against B16F10 cells by favoring an efficient presentation of B16F10-TAA to T lymphocytes and thus specific Tlymphocyte activation. The expression of allogenic molecules by tumor cells should reinforce antitumor rejection. This study evaluates the importance of alloantigens in the antitumor immune response, preliminary to antitumor clinical trials using semiallogenic fibroblasts expressing costimulatory molecules in the periphery of tumors.
B16F10 tumor cells were therefore cotransfected with cDNAs encoding CD40L and cDNA encoding CD70 molecules to obtain CD40L-CD70-expressing B16F10 cells. We showed that injections of CD40L-CD70-coexpressing tumor cells significantly slowed in vivo tumor growth. Moreover, CD40L-CD70-expressing B16F10 tumor cells were also transfected with cDNA encoding the allogenic MHC Class I molecule (H-2K d ). The coexpression of these three molecules resulted in a significant reduction of in vivo B16F10 tumor growth. Furthermore, in vivo and in vitro experiments suggest that NK cells and CD8 þ T lymphocytes are involved in this inhibition of tumor progression.
Materials and methods
Mice Female C57Bl/6 (H-2 b ) or C57BL/6 athymic nu/nu mice (6-to 8-week-old) were purchased from CERJ Janvier (Le Genest St-Isle, France) and C57BL/6J-bg J beige mice were purchased from Charles River Laboratoire (L'Arbresle, France), respectively, and were maintained in a pathogen-free animal facility prior to subcutaneous (s.c.) injection of tumor cells.
Tumor cell lines
The B16F10 cell line is an MHC Class I loss variant of B16, a spontaneous melanoma of C57Bl/6 (H-2 b ) mice. B16K1 is a genetically modified cell line obtained from B16F10 cells transfected with a syngenic MHC Class I molecule H-2K b . These tumor cells were maintained in vitro by serial passages in RPMI 1640 medium (BioWhittaker, Verviers, Belgique) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gibco-BRL, Cergy Pontoise, France). Tumor cell lines were injected into immunocompetent, athymic nu/nu or NK cell-deficient beige mice. To obtain s.c. tumors, 1 Â 10 5 cells in 100 ml of phosphate-buffered saline (PBS) were injected subcutaneously (s.c.) into the flank region. Tumor growth was determined by measuring the diameter in two dimensions of the tumors. The statistical significance was determined by Student's t-tests.
Vector generation and transfectant cells
The construction and characterization of the DFG murine CD40L (DFG CD40L) retroviral vector and the DFG human CD70 (DFG CD70) retroviral vector have been described previously. 6, 8 The DFG-based retroviral vector expresses the murine CD40L molecule along with an encephalomyocarditis virus (ECMV) internal ribosome entry site (IRES) neo R sequence-selectable marker, encoding resistance to G418. The DFG-based retroviral vector expresses the human CD70 molecule along with an IRES zeo R sequence-selectable marker, encoding resistance to Zeocyne. Murine and human CD70 molecules have an overall homology of 62% and the amino acids involved in the ligand receptor interaction showed 68% homology. It must be emphasized that species specificity is not observed at a functional level. 12 The vector pIREShygro-H-2K d was generated from two vectors: a procaryote vector pKC3-H-2K 
4). B16K1 and CD40L-CD70-H-2K
d -B16F10 cells were irradiated at 120 Gy. After washing, they were used as stimulating cells and accordingly coincubated in growth medium at 371C for 5 days with the spleen cell suspensions. The ratio of spleen cells to irradiated stimulating modified B16F10 or B16K1 cells was 10:1. The growth medium consisted of RPMI 1640 medium (BioWhittaker, Verviers, Belgium) supplemented with 10% FCS, 100IU IL-2, 100IU mIFN-g and penicillin/ streptomycin. At the end of the 5-day incubation, splenocytes were collected and used as the source of effector cells (E) for the cytotoxicity tests.
For the CRT assay, 10 6 target cells (T) B16K1 were labeled with 51 Cr during a 1 hour incubation at 371C in growth medium containing sodium chromate 51 Cr (100 mCi 51 Cr). After four washes with 10 mL RPMI, 0.1 mL RPMI containing 1 Â 10 4 51 Cr-labeled cells were incubated for 4 hours at 371C with spleen cells at varying E:T ratios. Afterwards, the percentage of specific cytolysis was calculated as: ((experimental 51 Cr releaseÀsponta-neous 51 Cr release)/(maximum 51 Cr releaseÀspontaneous 51 Cr release) Â 100).
Results

Inhibition of in vivo tumor growth induced by associated membrane expression of CD40L and CD70 costimulatory molecules
The melanoma cell line B16F10 was stably transfected with control vectors (mock) MFG Neo and MFG Zeo bearing resistance to G418 or Zeocyne, respectively, or with a vector encoding murine CD40L protein and neomycine resistance (DFG mCD40L Neo), or with a vector encoding human CD70 protein and Zeocyne resistance (DFG hCD70 Zeo), or with both vectors to obtain the coexpression of CD40L and CD70 molecules. Transfected tumor cells were selected in vitro with G418 (1 mg/mL) and/or with Zeocyne (0.1 mg/mL).
Membrane CD40L or CD70 expression was checked by cytofluorometry with either a FITC-conjugated antibody specific for murine CD40L or a PE-conjugated antibody specific for human CD70. All the experiments described in this work were carried out on pools of transfectant clones. To obtain these pools, we selected the three clones with the highest CD40L or CD70 expression. For negative controls, a pool of three B16F10 clones transfected with pMFG mock (Neo R and Zeo R ) was used. Tumor growth in vitro and in vivo of B16F10 mock is similar to that obtained with B16F10 wild type (wt) (data not shown). Furthermore, before each in vivo or in vitro experiment, cytofluorometry was used to check the membrane expression of both costimulatory molecules (Fig 1) . The expression of these molecules did not alter the in vitro proliferative rate of the selected tumor transfectant pools (data not shown).
The effect on in vivo B16F10 tumor growth of the expression of CD40L alone, or CD70 alone was compared with the effect of the coexpression of these two costimulatory molecules. Syngenic immunocompetent C57Bl/6 mice received sub-cutaneously in one flank 1 Â 10 5 B16F10 cells from mock transfectants or transfectants expressing CD40L and/or CD70 molecules. The tumor growths are illustrated in Figure 2 .
The growth of B16F10 tumors expressing CD40L or CD70 alone was slowed down but not significantly (P ¼ 0.08 and 0.38, respectively) compared to the mock tumor growth, whereas the coexpression of both molecules induced a significant (Pp0.01) inhibition of tumor growth.
Inhibition of in vivo tumor growth induced by associated membrane expression of an allogenic MHC Class I molecule with CD40L and CD70 costimulatory molecules
The ability of the coexpression of an allogenic MHC Class I molecule (H-2K d ) associated with CD40L and CD70 costimulatory molecules to slow down tumor growth was evaluated. B16F10 melanoma cells, which had previously been stably cotransfected with DFG -CD40L and DFG-CD70 vectors, were then stably transfected with pIREShygro-H-2K d vector. The construction of the vector pIREShygro was generated from Coexpression of costimulatory and allogenic molecules C Cormary et al two vectors pKC3-H-2K d (kindly provided by Dr F Lemonnier, Institut Pasteur, Paris) and pIREShygro, as described in Materials and methods. Tranfected tumor cells were selected in vitro with G418 (1 mg/mL), Zeocyne (0.1 mg/mL) and hygromycine (0.25 mg/mL). The membrane expression of CD40L and CD70 was checked as previously mentioned and the H-2K d expression was also checked by cytofluorometry with a PE-conjugated antibody specific for the H-2K d molecule. These membrane expressions are illustrated in Figure 3 . As previously, before each in vivo or in vitro experiment, membrane expression of these three molecules was checked.
Syngenic immunocompetent C57Bl/6 mice received an injection in one flank of 1 Â To evaluate the involvement of T lymphocytes and/or NK cells in this antitumor response, mock and modified tumor cells were injected in parallel into athymic nu/nu mice, NK cell-deficient beige mice and immunocompetent C57Bl/6 mice. Tumor growth is shown in Figure 5 . In nu/ nu mice (dotted lines), the growth of modified tumor cells is significantly slowed down (Po0.01) compared to that of mock tumor cells. This suggests that NK cells are involved in this antitumor immune response. This involvement is confirmed by the growth of modified tumor cells in immunocompetent mice (thick lines), which 
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Finally, the modified tumor cell growth in immunocompetent mice is significantly slowed down compared to kinetics of modified tumor cell growth observed in both nu/nu and beige mice, showing the implication of both T lymphocyte and NK cells in this antitumor response.
All these in vivo tumor growths show that in immunocompetent syngenic mice both T lymphocytes and NK cells are involved in the antitumor response induced by the injection of B16F10 coexpressing CD70 and CD40L costimulatory molecules associated with an allogenic MHC Class I molecule.
Delayed development of mock tumor growth by a simultaneous contralateral injection of CD40L-CD70-H-2K d -expressing B16F10 cells and mock tumor cells
Mice were injected with 1 Â 10 5 mock B16F10 cells in the right flank on day 0. In the left flank, the same mice were injected with 10 5
CD40L-CD70-H-2K
d -expressing B16F10 cells or with PBS alone for negative controls. The contralateral injections were simultaneous (day 0) or on days 3, 6 and 9 after mock tumor cell injections. Mock tumor growth was followed and Figure 6 illustrates the percentage of mice remaining mock tumor free.
When the contralateral injections were simultaneous (black histogram), a significant delay in mock tumor development was observed. Indeed, from day 14 all mice contralaterally injected with PBS alone had developed tumors whereas 40% of mice contralaterally injected with CD40L-CD70-H-2K d -B16F10 were tumor free on day 14 and 20% were still tumor free at day 19. However, when the CD40L-CD70-H-2K d -expressing B16F10 cells were contralaterally injected after the injection of mock tumor cells, although three injections were performed no effect was observed (hatched histogram). Indeed, at day 14, all mice had developed mock tumor growth.
Therefore, the induction of a delay in mock tumor growth is linked to the simultaneity of the contralateral injection with CD40L-CD70-H-2K d -expressing B16F10 tumor cells.
Induction of T-lymphocyte activation and cytotoxic activity in mice injected with CD40L-CD70-H-2K d -expressing B16F10 cells
To understand the slowing down of in vivo CD40L-CD70-H-2K d -expressing B16F10 tumor growth, the presence and the activity of effector immune cells were analyzed.
First, to specify which lymphocyte subpopulation is involved in the antitumor response observed in C57Bl/6 mice injected with CD40L-CD70-H-2K d -expressing B16F10 cells, the activation of T-cell subpopulations was analyzed via the expression of CD25 and CD27. Spleen and draining lymph node lymphocyte subpopula- 
Discussion
The extreme virulence of the B16F10 melanoma can be linked to its MHC Class I negativity 13 and to several characteristics including the secretion of IL-4 and IL-10 by T lymphocytes of mice injected with these tumor cells.
14 On the other hand, different laboratories have recently shown the involvement of CD4 þ CD25 þ regulatory T cells in B16F10 tumor tolerance and that the depletion of CD25 þ regulatory T cells further enhances the effects of immunotherapeutic treatments without increasing the incidence of autoimmunity. 15, 16 Nagaı¨'s group and Prasad et al have shown that an in vivo administration of anti-CD25 antibody alone did not affect the parental tumor growth. However, when an immunotherapy protocol using cytokines or vaccination is associated with depletion of CD25 þ T regulatory cells, the antitumor effects are enhanced and syngenic immunocompetent mice thus reject the B16F10 melanoma. Furthermore, Nagai et al have shown that CD8 þ T and NK cells are involved in B16F10 tumor rejection when antitumor treatment is associated with the depletion of CD25 þ regulatory T cells. 15 In the aim to counterattack the virulence of this murine melanoma, we have associated other strategies.
First, we chose two costimulatory molecules from the TNF superfamily, CD40L and CD70, in the aim to associate their different roles in tumor rejection by enhancing both specific and nonspecific cellular immune responses. CD40L, via an interaction with its receptor CD40, appears to be critical for dendritic cell maturation Cr. Three E:T ratios were tested in triplicate.
Coexpression of costimulatory and allogenic molecules C Cormary et al and migration to draining lymph nodes and for cytotoxic T-lymphocyte activation. 17, 18 CD70, via its receptor CD27, causes clonal expansion of activated lymphocytes and NK cells as well as their cytotoxic activity. 19, 20 It was shown in other tumor models that these costimulatory molecules were efficient in antitumor immunity, but when they were tested separately in the B16F10 model, their efficiency was slight. Indeed, we showed here that the slowing down of B16F10 tumor growth induced by CD40L expression alone is partial and we have previously shown that the injection of CD40L-expressing B16F10 cells in the periphery of, or contralaterally to mock B16F10 tumors is inefficient in reducing mock tumor growth. 6 Recently, we have shown that expression of CD70 (soluble or membrane forms) alone allows rejection of a MHC Class I-positive mammary tumor (TS/A) 8 but is inefficient in the B16F10 melanoma model (data not shown). However, here we show that the coexpression of CD40L and CD70 molecules by these tumor cells significantly slows down in vivo tumor growth, compared to the growth of cells expressing the costimulatory molecules individually. Concerning dendritic cell (DC) implication, it has been shown very recently by two independent teams an involvement of CD70 expressed on activated DC in the induction of CD8 þ Tcell responses and an interaction of CD40L and CD70 costimulatory molecules pathways leading to CD8 þ T-cell responses. In our work, the coexpression of these two costimulatory molecules should allow the tumor cells to become efficient APCs.
Second, we chose expression of an allogenic MHC Class I molecule to induce a strong activation of the immune system, and we show here that the slowing down of tumor growth is improved when the two costimulatory molecules CD40L and CD70 are expressed in association with an allogenic MHC Class I molecule (H-2K d ). Expression of the allogenic molecule H-2K d alone is not efficient in slowing down in vivo B16F10 tumor growth, indeed identical kinetics were observed with expression of CD40L, CD70 or H-2K d molecules alone (data not shown). It is necessary to associate the expression of these three molecules to significantly slow down B16F10 melanoma growth. Indeed 57% of immunocompetent syngenic mice injected with CD40L-CD70-H-2K d -B16F10 cells remained tumor free 21 days after tumor injection, whereas no mice injected with mock B16F10 were tumor free 12 days after tumor injection. Furthermore, we also showed a delay in mock tumor development when CD40L-CD70-H-2K d -expressing B16F10 cells were simultaneously injected contralaterally to mock tumor. However, this effect disappeared when modified B16F10 cells were injected 3 days after mock tumors instead of simultaneously.
Interestingly, Kelly et al 23 have shown that CD27/ CD70 interactions promote NK and T-cell-mediated tumor rejection. Here, in the B16F10 model, the coexpression of both costimulatory molecules and the allogenic molecule H-2K d induced an antitumor response involving both NK cells and T lymphocytes as shown by parallel injections in immunocompetent, athymic and beige mice. The involvement of T lymphocytes in the antitumor response directed against syngenic MHC Class I-negative tumor cells is probably linked to secondary expression of MHC Class I molecules due to IFN-g secretion in the periphery of the tumors. Indeed, we have previously shown that IFN-g is secreted in vivo in immunocompetent mice injected with B16F10 tumor cells genetically modified to express CD40L. 6 The involvement of activated T lymphocytes was confirmed by cytofluorometric analysis of spleen and draining lymph node cells 3 and 8 days after tumor injection. Moreover, it was shown that splenocytes from mice injected with CD40L-CD70-H-2K d cells develop the capacity to generate a cytotoxic response against the MHC Class I-positive B16K1 tumor cells.
TRP-2 peptide SVYDFFVWL has been described as the immunodominant TAA epitope expressed on B16 melanoma cell lines, 24 so it would be interesting to analyze the CD8 subpopulation specific for this TAA epitope with TRP-2/H-2K b tetramers, and to compare mice injected with mock, CD40L-CD70 or CD40L-CD70-H-2K d B16F10 cells. Therefore, we are currently assessing the B16F10 antitumor efficiency of injections of semiallogenic (H-2K b/d ) TRP-2 and CD40L-expressing fibroblasts secreting soluble CD70 costimulatory molecules. We have recently shown an effective antitumor immunity induced by secretion of soluble CD70 by allogenic fibroblasts in the periphery of MHC Class I-positive tumors 8 and Ku¨ndig et al 25 have shown that fibroblasts can be efficient antigen-presenting cells in lymphoid organs. Thus, this observation and recent work lead the way to the development of new antitumor immunotherapeutic protocols associating CD25 þ T-cell depletion and vaccination with semiallogenic-modified fibroblasts (see Fig 8) . We suggest genetically modifying HLA-A2-expressing fibroblasts to induce the expression of CD40L and an immunodominant TAA (such as MelanA/MART) and the secretion of soluble CD70. Then injecting these fibroblasts into HLA-A2 patients in the periphery of the tumor. These modified fibroblasts should induce an efficient antitumor response, linked to activating a specific T-lymphocyte response. Indeed, our results have shown: first, effective antitumor immunity induced by secretion of soluble CD70 by allogenic fibroblasts in the periphery of MHC Class I-positive tumors, 8 and second, an enhancement of antitumor response after injection of modified tumor cells expressing CD40L-CD70 costimulatory molecules and an allogenic MHC Class I antigen. Coexpression of costimulatory and allogenic molecules C Cormary et al
